



19th April 2017

To whom it may concern.

This is to confirm that the statement issued by Oxford University on the 12th March 2015 remains true today and that Huntleigh Healthcare continue to be the exclusive worldwide distributor, under licence from Oxford University Innovation, for the genuine Dawes-Redman CTG analysis developed by Dawes, Redman et al, at the University of Oxford.

Yours faithfully,

A handwritten signature in black ink, appearing to read "A Stoten".

Dr Adam Stoten
Chief Operating Officer, OUI.

Oxford University Innovation

Buxton Court, 3 West Way, Botley, Oxford OX2 0JB


T +44 (0)1865 280830 E enquiries@innovation.ox.ac.uk www.innovation.ox.ac.uk

Company No 2199542 Registered Office: University Offices, Wellington Square, Oxford OX1 2JD VAT No 490 7988 85



RJDL/ADMN2130

Dr Richard Liwicki
Deputy Director, Research Services



Yours Faithfully,

The University of Oxford has exclusively licensed its proprietary Dawes-Redman CTG analysis software to Huntleigh. Products produced by other companies will not contain the University's latest proprietary Dawes Redman algorithm and will not have been validated against the University's unique database containing over 100,000 clinical CTG records, and therefore may not perform in the same way.

To whom it may concern.

12 March 2015



Peter Cashin,
Managing Director,
Huntleigh Healthcare,
35, Portmanmoor Rd Ind Est,
Cardiff,
CF24 5HN

14 Frogmore,
London,
SW18 1HJ

27 February 2019

Dear Peter,

Reference: Dawes-Redman CTG analysis® - AIOG paper "A computer system for the numerical analysis of nonstress tests" (Am J Obstet Gynecol 2002;186:1095-1103.)

I am writing to you regarding my concerns relating to 3rd parties using the above referenced paper to produce a commercial CTG analysis product.

I hereby confirm that, as lead author of this paper, it **does NOT contain** all the information necessary to reproduce the genuine Dawes-Redman CTG analysis. Significant information was deliberately omitted from this paper to ensure that the Dawes-Redman CTG analysis could not be reproduced by 3rd parties.

I am concerned about 3rd parties who claim to have re-produced the analysis on the basis of this paper, and are marketing products as representing the Dawes-Redman CTG analysis, or as being equivalent to the Dawes-Redman CTG analysis, as it was in 2002.


These products are not the genuine Dawes-Redman CTG analysis, and have not been endorsed or authorised by me.

I have no knowledge as to the extent to which they may have been validated by other parties or their effectiveness as a robust & reliable CTG analysis tool.

Yours Sincerely,

A handwritten signature in black ink that reads "James Pardey". The signature is written in a cursive style with a long horizontal flourish extending to the right.

Dr James Pardey



Peter Cashin,
Managing Director,
Huntleigh Healthcare,
35, Portmanmoor Rd Ind Est,
Cardiff, CF24 5HN

Prof CWG Redman
Nuffield Department of Women's and
Reproductive Health
John Radcliffe Hospital
Oxford, OX3 9DU

03 February 2019

Dear Peter,

Reference: Dawes-Redman CTG analysis[®] - Pardy et al 2002. "A computer system for the numerical analysis of nonstress tests" (Am J Obstet Gynecol 2002;186:1095-1103.)

I am writing to you about my concern that 3rd parties have used the above partial description of the Dawes-Redman system, on its own, to produce a commercial CTG analysis product claiming to simulate the authentic Dawes-Redman system as marketed by Huntleigh Healthcare, either in its present form, or as previously marketed in 2002.

I hereby confirm that, as the co-inventor of the Dawes-Redman CTG analysis and co-author of this paper, the paper does NOT contain all the information required to faithfully reproduce the genuine Dawes-Redman CTG analysis.

These products are not the genuine Dawes-Redman CTG analysis, have not been endorsed or authorised by me or Oxford University and have not been validated against our unique database.

I have no knowledge as to the extent to which they may have been validated by others or to their effectiveness as a robust and reliable CTG analysis tool.

Huntleigh Healthcare continues to hold the worldwide exclusive distribution licence for the only genuine Dawes-Redman CTG analysis. It should also be noted that the latest version is substantially more powerful than the version we had in 2002, benefiting from a 35% larger database (100,000 records) and 16 years of algorithm enhancements based on continued research and customer feedback since that time. These enhancements have not been published and can not be used in any 3rd party product.

Yours sincerely,

A handwritten signature in black ink that reads 'Chris Redman'.

Chris Redman,
Professor Emeritus
Oxford University

Christopher.redman@wrh.ox.ac.uk
www.wrh.ox.ac.uk
John Radcliffe Hospital Oxford, OX3 9DU, UK
Tel: +44 7950 270 860 (mobile); +44 1865 221009 (direct landline)

a clinical risk. Claims that these products reflect the Dawes-Redman CTG analysis may also infringe regulatory compliance where this applies.

It is further advised that the above referenced paper presented a review of the Dawes-Redman CTG analysis as it was in 2002. Continued research and development, together with over 16 years' further feedback from customers, has significantly enhanced the genuine analysis, now based on a database of 100,000 traces. This continued development has highlighted significant weaknesses in the 2002 version which have been addressed in the latest release.

Huntleigh Healthcare hereby formally inform you that it is our intention to make this letter, and copies of the signed Pardey & Redman letters, available to our customers and the wider worldwide market place in 14x days from the date of this letter. As a reputable company we believe that it is right & proper to give you advance notice of this to allow you to prepare for the market reaction to this information.

In the event that any 3rd party continues to market their analysis products as representing, either directly, or indirectly, the Dawes-Redman CTG analysis, Huntleigh Healthcare reserves the right to take appropriate action to address this as may be deemed appropriate.

If you do not market or sell such a product, either currently, or have not done so since the publication of the 2002 paper, please ignore this letter.

Yours faithfully,



Peter Cashin

Managing Director,
Huntleigh Healthcare Limited.

Enclosed:

Copy of letter from Prof. Chris Redman
Copy of letter from Dr. James Pardey
Copy of letter from Oxford University (12/03/2015)
Copy of letter from Oxford University (19/04/2017)

14th March 2019

To whom it may concern

Notice relating to fetal monitoring products

Dear Sir/Madam,

Reference: Dawes-Redman CTG analysis

We understand that you have placed on the market one or more products which include an analysis which you claim to be, or to be equivalent to, the Dawes-Redman® CTG analysis as developed by Dawes, Redman et al at Oxford University, UK.

A paper regarding the Dawes-Redman® CTG analysis was published in the American Journal of Obstetrics & Gynecology in 2002 (Pardey et al Am J Obstet Gynecol 2002 186(5)1095-1103).

We would like to inform you that:

- Huntleigh Healthcare hold an exclusive, worldwide licence to distribute the only genuine Dawes-Redman CTG analysis
- The above referenced paper did not state that the information included in the paper gave all the information necessary to fully reproduce the Dawes-Redman CTG analysis
- The lead author of this paper, Dr. James Pardey, has confirmed that this paper did not include all the information and that some details were deliberately omitted in order to prevent the analysis from being reproduced.
- Copies of 2x signed letters are enclosed confirming the above – one from Dr. James Pardey & one from Prof. Chris Redman
- Copies of supporting statements from Oxford University relating to our exclusive worldwide distribution licence are also enclosed
- No 3rd party reproductions of the information in the above referenced paper have ever been in anyway approved, endorsed or in any way validated by Oxford University or Chris Redman et al., and they have not been validated against the Oxford University database.

It is therefore the case that any analysis, other than Huntleigh Healthcare's products, claiming to be based on the Dawes-Redman CTG analysis, is not a faithful reproduction, is of unknown provenance, will not perform in the same way as the genuine Dawes-Redman CTG analysis and does not reflect the Dawes-Redman criteria for CTG analysis. Use of such analyses, on the presumption of them being equivalent to the genuine Dawes-Redman CTG analysis, may present